直接口服抗凝剂 (DOAC) 与左心室血栓中的维生素K对抗剂:更新的元分析
Dhan B Shrestha1, Sagun Dawadi2, Bishal Dhakal2
1Department of Internal Medicine Mount Sinai Hospital Chicago Illinois USA.
Health science reports
|November 29, 2023
概括
与维生素K对抗剂 (VKA) 相比,直接口服抗凝剂 (DOAC) 显示左心室高层血栓 (LVT) 解析,并降低了中风和出血的风险. DOACs还显示,LVT患者的死亡率下降的趋势.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 左心室血栓 (LVT) 治疗的临床指南缺乏口服抗凝剂的比较疗效数据.
- 目前的证据不足以指导直接口服抗凝剂 (DOAC) 和维生素K对抗剂 (VKA) 之间的选择.
研究的目的:
- 在被诊断为LVT的患者中,比较DOAC与VKA的疗效和安全性.
- 评估结果,包括 LVT 解析,死亡率,中风,栓塞和出血事件.
主要方法:
- 进行了一项元分析,搜索了四个数据库,比较到2023年8月19日的LVT治疗的DOAC和VKA研究.
- 包括的研究包括随机对照试验和观察性研究.
- 用RevMan 5.4分析数据,以确定关键结果的几率比率.
主要成果:
- 分析了33项涉及3959名患者的研究.
- 与VKAs相比,DOAC显示了较高的LVT解析率 (72.59%对67.49%).
- 使用DOAC与明显较低的出血率 (9.60%与13.19%) 和中风 (7.54%与11.04%),以及极限显著较低的死亡率 (11.71%与18.56%) 相关.
结论:
- 直接口服抗凝剂 (DOAC) 在LVT解决方面比维生素K抗剂 (VKA) 更有效.
- DOACs显著降低了LVT患者出血和中风的风险.
- 与VKAs相比,DOACs对LVT提供了一个潜在的更安全,更有效的治疗选择.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
711
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
711
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
532
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
532
Disorders of Hemostasis
926
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
926


